A randomized study of two dose levels of intravenous (IV) clofarabibe (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Jabbour, E. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Kashani, F. Ravandi [1 ]
Borthakur, G. [1 ]
Estrov, Z. [1 ]
Gandhi, V. [1 ]
Byrd, A. [1 ]
Kwari, M. [1 ]
Faderi, S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6504
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    [J]. BLOOD, 2013, 122 (21)
  • [22] A SYSTEMATIC LITERATURE REVIEW (SLR) OF THE CLINICAL EFFICACY AND SAFETY EVIDENCE ASSOCIATED WITH TREATMENT OF PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS)
    Papadakis-Sali, A.
    Bobrowska, A.
    Shaw, S.
    Radford, M.
    Estrella, Sabate E. J.
    Asukai, Y.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S18 - S19
  • [23] Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Adesanya, Afoluso Ronnee
    Zbyszewski, Patrick S.
    Woodman, Richard C.
    Fenaux, Pierre
    Silverman, Lewis R.
    [J]. BLOOD, 2019, 134
  • [24] Effectiveness of Azacitidine in Frontline Higher-Risk Myelodysplastic Syndrome: A Retrospective Cohort Study of 382 Patients
    Nishathan, Rajakumaraswamy
    Mitul, Gandhi
    Andrew, H. Wei
    David, A. Sallman
    Navel, G. Daver
    Shuyuan, Mo
    Shahed, Iqbal
    Manli, Chen
    Yunfei, Wang
    Paresh, Vyas
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S15 - S15
  • [25] Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
    Morita, Kiyomi
    Bravo, Guillermo Montalban
    Sasaki, Koji
    Bodden, Kristy R.
    Wang, Feng
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Takahashi, Koichi
    Jabbour, Elias
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Ohanian, Maro
    Pierce, Sherry A.
    Azab, Mohammad
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2020, 136
  • [26] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Zimmerman, Cassie
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Kantarjian, Hagop
    Zell, Katrina
    Wang, Quiqing
    Gore, Steven D.
    Nazha, Aziz
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    [J]. BLOOD, 2014, 124 (21)
  • [27] ECONOMIC IMPACT OF TRANSFORMATION TO ACUTE MYELOID LEUKEMIA (AML) AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HIGHER-RISK MDS) IN THE UNITED STATES: RETROSPECTIVE MATCHED COHORT STUDY
    Kota, V.
    Ogbonnaya, A.
    Farrelly, E.
    Schroader, B. Kanz
    Kristo, F.
    Raju, A.
    Dalal, M.
    [J]. LEUKEMIA RESEARCH, 2021, 108 : S26 - S27
  • [28] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    [J]. BLOOD, 2008, 112 (11) : 88 - 89
  • [29] Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Sasaki, Koji
    Kadia, Tapan M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Khoury, Joseph D.
    Patel, Keyur P.
    Bueso-Ramos, Carlos E.
    Daver, Naval G.
    Borthakur, Gautam
    Jain, Nitin
    DiNardo, Courtney D.
    Konopleva, Marina
    Verstovsek, Srdan
    Pemmaraju, Naveen
    Estrov, Zeev
    Miller, Darla
    Maduike, Rita
    Faderl, Stefan
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2016, 128 (22)
  • [30] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2014, 124 (21)
12345